Nilai Dipunlarasaken Utang lan Kas: Serina Therapeutics, Inc. (SER)

Serina Therapeutics, Inc. (SER) develops innovative POZ-based polymer carriers for infrequent drug administration, which, combined with the development of delivery systems for chronic CNS disorder therapies, establishes a foundation for long-term patent utilization. This daily price chart reflects that the business valuation is 29.47. However, the absence of recurring revenue and the potential for failed Parkinson's disease trials create a risk of liquidity shortages.

Enterprise Value (EV) represents the total buyout price of a business, combining market capitalization and net debt. For Serina Therapeutics, Inc. (SER), this metric reflects the cost of acquiring rights to polymer drug delivery systems. The enterprise value trend on this chart demonstrates the market's valuation of potential future licensing revenues. Investors can see the actual scale of capital net of liquid assets, which determines the fundamental stability of Serina Therapeutics, Inc. (SER) during the drug development period.